Provenge
Author: Zachary McLellan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Provenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed on approximately 95% of prostate tumor cells. The vaccine is administered alongside a granulocyte-macrophage colony-stimulating factor adjuvant. Upon injection, the PAP-loaded dendritic cells cause activation of T cells, which recognize the target antigen and destroy prostate tumor cells.
TABLE OF CONTENTS
4 Product Profiles
4 Provenge : Prostate cancer
LIST OF FIGURES
7 Figure 1: Provenge for prostate cancer – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Provenge for prostate cancer
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Provenge for prostate cancer
11 Figure 4: Provenge sales for prostate cancer in the US, 2017–26
LIST OF TABLES
4 Table 1: Provenge drug profile
6 Table 2: Provenge pivotal Phase III data in prostate cancer
11 Table 3: Provenge sales for prostate cancer in the US ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
JP Morgan Healthcare Conference Review 
Sign up to the